Results and Discussion
gesting that the vulval-bursting phenotype of let-7 was not suppressed merely because of the lack of a vulva. let-60 and let-7 are both expressed in hypodermal let-60/RAS as a Target . We found that postembryonic capitulates the temporal expression of let-7 and is temreduction of function of let-60 by feeding RNA interferporally expressed in seam cell tissues affected in the ence (RNAi) also partially suppressed let-7(n2853) in a let-7 mutant (Johnson et al., 2003). We examined the reproducible manner. While 5% of let-7 mutants grown expression pattern of mir-84, the closest let-7 relative, on control RNAi survived at the nonpermissive temperby fusing 2.2 kilobases (kb) of genomic sequence imature of 25°C (n = 302), 27% of let-7(n2853); letmediately upstream of the miR-84 encoding sequence 60(RNAi) animals survived (n = 345) (Figures 2A and to the green fluorescent protein (gfp) gene. mir-84::gfp 2B). Thus, similar to other known let-7 targets, let-60 lf was first observed in the somatic gonad in larval stage partially suppresses the let-7(n2853) lethal phenotype, 1 (L1). In L3 animals, strong expression was observed suggesting that let-7 lethality may at least partially be in uterine cells including the anchor cell (AC), and weak caused by overexpression of let-60. However letdynamic expression was observed in the vulval precur-60(RNAi) did not appear to suppress the let-7 seam cell sor cells (VPCs) (Figure 3 3P, S1C, and S1D). Subsequent VPC expression in the expression was observed in all the VPCs except for P6.p at the stage when their fate in vulval development mid to late L3 stage was restricted to the daughters (Pn.px) of P5.p and P7.p with weaker GFP first appearis determined by signaling from the AC ( Figure 3O ; Ambros, 1999) , suggesting that mir-84 could play a role ing in the P6.p daughters just before their division into P6.pxx. Thereafter, equivalent expression was obin vulval cell fate determination. In the L4 stage, GFP expression was maintained in the AC and other uterine served in the granddaughters (Pn.pxx) of P5.p, P6.p, and P7.p (Figures 3E and 3F) . We note that mir-84::gfp cells, appeared weakly in hypodermal seam cells (A. 
called mir-84(+++)). These animals expressed elevated
We searched for LCSs in the 3#UTRs of all genes levels of miR-84 ( Figure 4G ) and displayed abnormal known to play a role in vulval development (Table S1) 
, 2004). Reducing the activity of let-7 in HeLa cells relet-7 and mir-84 regulate let-60/RAS expression through its 3#UTR in seam and vulval cells, cells in which they
sulted in an w70% increase in RAS protein levels (Figures 5C and 5D ). These results, combined with the reare all naturally expressed. Given that the 3#UTR of let-60/RAS contains multiple let-7/mir-84 complementary ciprocal experiment using pre-let-7 miRNAs discussed above, strongly suggest that let-7 negatively regulates sites, we propose that this regulation is direct. the expression of RAS in human cells. Figures 6A and 6B) , while HRAS was not tested. Our all three human RAS 3#UTRs contain multiple putative results demonstrate that the 3#UTRs of NRAS and let-7 complementary sites with features of validated KRAS contain regulatory information, sufficient to down-C. elegans LCSs (Figures 1B, 1C, and 1D) . Many of regulate the reporter. Little is known about the exact these are conserved in rodents, amphibians, and fish characteristics that convey functionality to a miRNA ( Figure S4) , suggesting functional relevance. The prescomplementary site, and future work may reveal the difence of putative LCSs in human RAS 3#UTRs suggests ferences between the NRAS and KRAS 3#UTRs. that mammalian let-7 family members may regulate huAs with the endogenous RAS experiments described man RAS in a manner similar to the way let-7 and mirabove, we performed the reciprocal experiment wherein 84 regulate let-60/RAS in C. elegans.
We fused the 3#UTR of human NRAS and KRAS to a let-7 Complementary Sites in Human RAS
we cotranfected HeLa cells with the RAS 3# UTR reporter constructs and the let-7a antisense inhibitor molecule (or a control scrambled molecule). Cells transHuman RAS Expression Is regulated fected with the let-7a inhibitor relieved repression by let-7 in Cell Culture exerted on the reporter relative to the control transfecMicroarray analysis on six different cell lines revealed that HepG2 cells express let-7 at levels too low to detions ( Figure 6C ). Since we observe a loss in the extent We utilized a miRNA microarray to examine expresTo test this hypothesis, we isolated total RNA and total protein from the tumor and normal adjacent tission levels of members of the let-7 gene family in tissue from 21 different cancer patients, including 12 lung sues of three new lung cancer patients with squamous cell carcinoma. The RNA samples were split and half cancer patients with squamous cell carcinomas (stage IB or IIA). We found that the let-7 miRNAs were reduced was used for Northern analysis to measure let-7c and U6 snRNA. The other halves of the RNA samples were in expression in a number of the tumors relative to the normal adjacent tissue (NAT) samples from the same used for real-time PCR to measure the NRAS mRNA, 18S rRNA, and B-actin mRNA. The protein samples patients ( Figure 7A) . Interestingly, we found that let-7 was expressed at lower levels in all of the lung tumor were used for Western analysis to assess RAS and GAPDH protein levels. As seen in Figure 7C , RAS protissues (Figure 7 ) but only sporadically in other tumor types. A similar finding was independently discovered tein was present in the tumors at levels at least 10-fold higher than in the normal adjacent samples from the (Takamizawa et al., 2004) . On average, let-7 was expressed in lung tumors at less than 50% of what it was same patients. Consistent with the miRNA array results for other lung cancer samples, all three lung tumor expressed in the associated normal lung samples (Figure 7A) . We used Northern analysis to measure let-7c samples had 4-to 8-fold lower levels of let-7 than did the corresponding NAT samples. Interestingly, the first in the tumor and NAT samples for the two patients from which we purified enough RNA (samples represented and third lung cancer samples had similar levels of NRAS mRNA in both the tumor and NAT while the by the first and fifth lung cancer bars in Figure 7A ). Consistent with the microarray results, Northern analysis second sample pair had significantly higher levels of NRAS mRNA in the tumor sample. In our limited analyverified that the expression of let-7c was 65% lower in the tumor of patient 1 and 25% lower in the tumor of sis, RAS protein levels correlate poorly with NRAS mRNA levels but very well with let-7 levels, suggesting patient 5 ( Figure 7B electroblotting at 200 mA in 0.5× TBE for 2 hr. The Northern blot All RNAi experiments were done in parallel to an empty vector was dried and then incubated overnight in 10 ml of ULTRAhyb-(L4440) feeding control. See Supplemental Experimental ProceOligo (Ambion) with 10 7 cpm of a radio-labeled transcript compledures for details on the let-60; let-7 double mutant cross.
mentary to let-7c. The blot was washed 3 × 10 min at room temperature in 2× SSC, 0.5% SDS and then 1 × 15 min at 42°C in 2× SSC, 0.5% SDS. Overnight phosphorimaging using the Storm system let-7/RAS Association in Mammalian Cells (Amersham) revealed let-7c. The process was repeated using a raHeLa S3 cells grown in D-MEM (GIBCO) supplemented with 10% dio-labeled probe for 5S rRNA. fetal bovine serum (GIBCO) were cotransfected in 12-well plates using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol using 1.0 g/well of Pp-luc-expressing plasmid Lung Tumor Protein/Northern/mRNA Analysis (pGL3-Control from Promega, pGL3-NRAS S pGL3-NRAS L and Total RNA and protein were isolated from tumor and normal adjapGL3-KRAS) and 0.1 g/well of Rr-luc-expressing plasmid (pRL-TK cent tissue samples from three lung cancer patients using the mirfrom Promega). 24 hr posttransfection, the cells were harvested Vana PARIS Kit (Ambion). let-7 miRNA and U6 snRNA were meaand assayed using the Dual Luciferase assay as described by the sured using the Northern procedure described above. NRAS and manufacturer (Promega). HeLa cells grown as above were trans-B-actin mRNA as well as 18S rRNA were quantified by real-time fected in 24-well plates with 30 pmol of Anti-miR let-7 or negative RT-PCR using primers specific to each of the target RNAs. RAS and GAPDH protein were measured by Western analysis using the control 1 inhibitors (Ambion) using Lipofectamine 2000. Three days 
